Insider Buying: Wayne Coll Acquires Shares of Precision Optics C

Wayne Coll, CFO of Precision Optics Corp Inc (POCI), recently purchased 20,833 shares, increasing his total holdings to 35,239 shares. This purchase reflects a positive insider sentiment, with three insider buys and no sells in the past year. The stock is currently trading at $3.60, with a GF Value of $5.39, suggesting it is modestly undervalued.

Original reporting
Published Apr 2, 2026, 3:06 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Apr 2, 2026, 3:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$POCI
Bullish
medium confidence
Mentioned
$POCI
Relevance
6/10
AlphAI data visualization · based on GuruFocus
Decision brief

The 30-second read

$POCIBullishMed
01

Why it matters

The insider purchase, combined with the stock trading below its GF Value, suggests a potential undervaluation and buying opportunity.

02

Market read

The news indicates a bullish signal for POCI, with moderate trading implications for short-term traders.

03

What to watch

Potential macroeconomic headwinds or sector-specific challenges could offset insider optimism.

Relevance 6/10Timing: short-term (next 1-3 months)

Background

Wayne Coll, CFO of Precision Optics Corp Inc, purchased 20,833 shares, increasing his holdings to 35,239 shares, reflecting positive insider sentiment.

Company-level read

Ticker impact

$POCIBullishMedium confidence
Context

The insider buying activity and undervaluation suggest potential positive movement.

Expected impact

Moderate upward price movement expected within 1-3 months.

Evidence & confidence

Insider buying is a bullish indicator; however, the stock's current trading at a discount to GF Value supports this view, though external market factors could influence the outcome.

Market effects

The optics and technology sector may see increased investor interest due to insider confidence signals.

Limited regional impact; company operates primarily in the US.

Minimal global market relevance given company's size and sector.

Counterpoint

Insider buying may be motivated by personal reasons or limited to a small number of shares, not necessarily indicating broader company confidence.

Key entities

  • Wayne Coll

    CFO of Precision Optics Corp Inc.

  • Precision Optics Corp Inc

    Manufacturer of optical components and systems.

Related articles

$POCIMed

Precision Optics Reports First Quarter Fiscal 2027 Financial Results

PRECISION OPTICS CORPORATION, INC. (POCI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRECISION OPTICS CORPORATION 550 King Street, Bldg. A, Suite 100 Littleton, MA 01460 978 / 630-1800 NEWS RELEASE POC26-XXXX FOR IMMEDIATE RELEASE Monday, November 16, 2026 Precision Optics Reports First Quarter Fiscal 2027 Financial Results Conference Call Scheduled

$POCIMed

Precision Optics Reports Fourth Quarter and Fiscal Year 2026 Financial Results

PRECISION OPTICS CORPORATION, INC. (POCI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRECISION OPTICS CORPORATION 550 King Street, Bldg. A, Suite 100 Littleton, MA 01460 978 / 630-1800 NEWS RELEASE POC26-0012 FOR IMMEDIATE RELEASE Monday, September 28, 2026 Precision Optics Reports Fourth Quarter and Fiscal Year 2026 Financial Results Conference Call

$CGONMed

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

Biotech stocks moved amid clinical and regulatory news. CG Oncology's bladder cancer drug met its primary endpoint, reducing recurrence risk by 68%. Lexeo's gene therapy showed promising interim data. Summit Therapeutics' lung cancer drug received an FDA rejection, and Aclaris' atopic dermatitis treatment missed Phase 2 goals. The S&P 500 and Nasdaq fell 1.92% and 2.49%, respectively, according to CNBC.